abbott diabetics

[anonymous]

What's the base pay for the DSS role? Considering one of your openings, have diabetes sales experience.
Honest replies only, Thx!

 

[anonymous]

What's the base pay for the DSS role? Considering one of your openings, have diabetes sales experience.
Honest replies only, Thx!

do you know Duncan? Are you male or female? How well do you dance

 

[anonymous]

What's the base pay for the DSS role? Considering one of your openings, have diabetes sales experience.
Honest replies only, Thx!

$80K base, $35-40K bonus at plan

 

[anonymous]

$80K base, $35-40K bonus at plan

No the base is higher for dss’s. I think 85 was for the dsa’s

 

[anonymous]

No the base is higher for dss’s. I think 85 was for the dsa’s

than why did you ask if you claim to already know. Loser troll.

 

[anonymous]

Dunky retired. Saw it on LinkedIn....

 

[anonymous]

than why did you ask if you claim to already know. Loser troll.

Hey, I'm the op who asked! Not the person your yelling at. Seriously, I heard the DSS (specialty not associate) role paid more than the junior DSA role. Anyone know the DSS starting pay? My experience is from a major diabetes pharma co. Honest replies only, Thanks!!

 

[anonymous]

All base pay is under 100k. If you high end pharma you will have to take pay cut.

 

[anonymous]

All base pay is under 100k. If you high end pharma you will have to take pay cut.

Not true!

 

[anonymous]

What's the average DSS base salary?
And.....average annual QTR bonus?

 

[anonymous]

Not true!

it’s very true dummy.

 

[anonymous]

What's the average DSS base salary?
And.....average annual QTR bonus?

If compensation drives you keep on walking my friend. ADC touts itself for its top line technology while paying its reps below industry standards.

 

[anonymous]

Dex is ADCs daddy end of story.

 

[anonymous]

Dex is ADCs daddy end of story.

Really? CGM sales for ADC are about $4.2B/yr. DexCom is $2.5B/yr. Libre 3 is EU and FDA approved and Abbott has spent $500M to setup manufacturing for Libre 3 sensors. The G7 is not as good as Libre 3 and the FDA rejected the G7 approval due to SW issues. DexCom may remain a player in CGM....but second fiddle to ADC.

 

[anonymous]

Really? CGM sales for ADC are about $4.2B/yr. DexCom is $2.5B/yr. Libre 3 is EU and FDA approved and Abbott has spent $500M to setup manufacturing for Libre 3 sensors. The G7 is not as good as Libre 3 and the FDA rejected the G7 approval due to SW issues. DexCom may remain a player in CGM....but second fiddle to ADC.

“Not as good as Libre”? Based on what? Nobody has any head to head data Homer. You making false claims? Careful little fella!

 

[anonymous]

“Not as good as Libre”? Based on what? Nobody has any head to head data Homer. You making false claims? Careful little fella!

G7 devices have had persistent moisture issues, manufacturing is very slow to catch up to Libre 2 volumes, form factor is way larger than Libre 3: basically, G7 just ha snot been used enough (by volume, geography, patient demographic) to show any meaningful reliability & accuracy data to compete with Libre 2. G7 worked very well in a lab setting - that is a far cry from high-volume reliability in daily use globally.

 

[anonymous]

G7 devices have had persistent moisture issues, manufacturing is very slow to catch up to Libre 2 volumes, form factor is way larger than Libre 3: basically, G7 just ha snot been used enough (by volume, geography, patient demographic) to show any meaningful reliability & accuracy data to compete with Libre 2. G7 worked very well in a lab setting - that is a far cry from high-volume reliability in daily use globally.

You seem to like making false comparative claims. Fools like you are why companies land on CIA’s draining billions of dollars.

 

[anonymous]

G7 devices have had persistent moisture issues, manufacturing is very slow to catch up to Libre 2 volumes, form factor is way larger than Libre 3: basically, G7 just ha snot been used enough (by volume, geography, patient demographic) to show any meaningful reliability & accuracy data to compete with Libre 2. G7 worked very well in a lab setting - that is a far cry from high-volume reliability in daily use globally.

Bottom line....Libre 3 has had its shake down run in Germany for a year and a half to eliminate the bugs. Now that this limited release is done Libre 3 is ready for general wide release. G7 was just approved by the EU a few months back and does not have FDA approval. The G7 is a year or more behind Libre 3 in terms of product maturity. And, as mentioned by others, Abbott has the money and has spent 1/2 a billion bucks on a state-of-the-art sensor manufacturing plant. DexCom is way behind and in trouble....

 

[anonymous]

Bottom line....Libre 3 has had its shake down run in Germany for a year and a half to eliminate the bugs. Now that this limited release is done Libre 3 is ready for general wide release. G7 was just approved by the EU a few months back and does not have FDA approval. The G7 is a year or more behind Libre 3 in terms of product maturity. And, as mentioned by others, Abbott has the money and has spent 1/2 a billion bucks on a state-of-the-art sensor manufacturing plant. DexCom is way behind and in trouble....

more unproven shady unethical false claims. the fda will slam you.

 

[anonymous]

more unproven shady unethical false claims. the fda will slam you.

Typical Trumper....state a few simple facts. FDA rejected G7 due to SW issues, Abbott news shows the Libre 3 investment, MARD for Libre 3 is 6.8% better than G7,etc, and the Trumper denies facts in favor of conspiracies and opinion.